Live Q&A: At-Risk Patients Hidden in Plain Sight: Real-World Strategies for Screening and Treating Hepatitis B Virus

CMEO Webcast

Premiere Date: Wednesday, September 23, 2020

This activity offers CE credit for:

  1. Physicians (CME)
  2. Pharmacists (ACPE)
  3. Other


All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date: Thursday, September 23, 2021

Begin Activity Now

Faculty


Kris V. Kowdley, MD, FACP, FACG, AGAF, FAASLD Kris V. Kowdley, MD, FACP, FACG, AGAF, FAASLD 
Director, Liver Institute Northwest
Clinical Professor, Elson S. Floyd College of Medicine
Washington State University
Spokane, WA

Statement of Need

Chronic hepatitis B virus (HBV) remains a global epidemic, resulting in significant morbidity and mortality. In 2015, there were 257 million people worldwide infected with HBV. In 2016, only 10.5% were diagnosed, with only 16.7% receiving treatment, and without intervention there are 19 million deaths anticipated by the end of 2020. These numbers are startling as they exist despite the availability of effective treatment, and this is in part due to lack of clinician knowledge on screening and managing patients with HBV as well as lack of ability to foster retention for wrap-around services.

In 2018, The American Association for the Study of Liver Diseases released an updated guidance document for the prevention, diagnosis, and treatment of chronic HBV, including recommendations for screening, testing, counseling, and use of the newest antiviral treatment. Early detection is imperative for prevention and treatment, and this puts internists and primary care clinicians on the front lines to reduce HBV's global disease burden.

This live question and answer session is your opportunity to ask questions based on the CME Outfitters virtual symposium where expert faculty utilized augmented reality to add visualization to their discussion of how to implement routine screening protocols for HBV in primary care settings, how to optimize the efficacy and safety profiles of current agents, and the importance of providing culturally appropriate counseling and support services to patients, which will ensure understanding of their disease and promote retention in care. To view the full activity ahead of this live Q&A, click here.

Learning Objectives

At the end of this CE activity, participants should be able to:

  • Implement routine screening protocols for HBV in primary care settings and utilize results to drive guideline-directed care.
  • Optimize efficacy and safety profiles of current agents when initiating or switching treatment in patients with HBV.
  • Provide culturally appropriate counseling and support services to patients in order to ensure understanding of their disease and promote retention in care.

The following learning objectives pertain only to those requesting CNE or CPE credit:

  • Explain routine screening protocols for HBV in primary care settings and how to utilize results to drive guideline-directed care.
  • Describe efficacy and safety profiles of current agents for initiating or switching treatment in patients with HBV.
  • Discuss culturally appropriate counseling and support services for patients in order to ensure understanding of their disease and promote retention in care.

Financial Support

Supported by an educational grant from Gilead Sciences, Inc.

Target Audience

Internists, primary care physicians, PAs, nurse practitioners, and pharmacists

Credit Information

CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Outfitters, LLC, designates this live activity for a maximum of .5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CPE Credit (Pharmacists):
ACPE CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. .5 contact hour (0.05 CEUs). Universal Activity Number:
Live: 0376-0000-20-124-L01-P

Type: knowledge-based

Note to PAs: PAs may claim a maximum of .5 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME or a recognized state medical society.

Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

Credit request forms and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately. This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit https://www.cmeoutfitters.com/privacy-and-confidentiality-policy

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Kowdley reports he receives research support from Conatus Pharmaceuticals Inc.; CymaBay Therapeutics; Enanta Pharmaceuticals, Inc.; Genfit; Gilead Sciences, Inc.; GlaxoSmithKline; HighTide Therapeutics Inc.; Intercept Pharmaceuticals, Inc.; and Zydus Pharmaceuticals, Inc. He serves on the advisory committee for Assembly Biosciences, Inc.; Blade Therapeutics; Boehringer Ingelheim; Merck & Co., Inc.; and Roche. He is on the speakers bureau for AbbVie Inc.; Gilead Sciences, Inc.; and Intercept Pharmaceuticals, Inc.

Kashemi D. Rorie, PhD (planning committee) has no disclosures to report.

Susan Perry (planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty has been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).


This document was last modified on:

MMQ-101-092320-47